Biocardia Says Independent Data Safety Monitoring Board Has Completed Its Prespecified Data Review For The Ongoing Phase 3 Pivotal CardiAMPCell Therapy Heart Failure Trial, Recommending Pausing The Trial Pending The One-year Follow-up Outcomes Analysis
Portfolio Pulse from Benzinga Newsdesk
Biocardia has announced that the Independent Data Safety Monitoring Board has completed its prespecified data review for the ongoing Phase 3 Pivotal CardiAMPCell Therapy Heart Failure Trial. The board has recommended pausing the trial pending the one-year follow-up outcomes analysis.
July 24, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biocardia's ongoing Phase 3 trial for CardiAMPCell Therapy has been recommended to pause for a one-year follow-up outcomes analysis. This could potentially delay the product's market entry.
The recommendation to pause the trial for a one-year follow-up outcomes analysis could potentially delay the product's market entry. This could have a negative impact on Biocardia's stock price in the short term as investors may see this as a setback.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100